Litigation Details for ACTELION PHARMACEUTICALS LTD. v. NATCO PHARMA LIMITED (D.N.J. 2019)

ACTELION PHARMACEUTICALS LTD. v. NATCO PHARMA LIMITED (D.N.J. 2019)

Docket		Date Filed	2019-05-28
Court	District Court, D. New Jersey	Date Terminated	2019-11-26
Cause	28:1338 Patent Infringement	Assigned To	Brian R. Martinotti
Jury Demand	None	Referred To	Douglas Arpert
Parties	NATCO PHARMA LIMITED
Patents	8,309,126
Attorneys	KEITH J. MILLER
Firms	Robinson Miller LLC, Ironside Newark
Link to Docket	External link to docket

Details for ACTELION PHARMACEUTICALS LTD. v. NATCO PHARMA LIMITED (D.N.J. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-05-28				External link to document
2019-05-28	1	Complaint	prior to the expiration of U.S. Patent No. 8,309,126 (the “’126 patent”). … This is a civil action for patent infringement arising under the patent laws of the United States, … THE PATENT-IN-SUIT 11. The ’126 patent, entitled “Dispersible Bosentan…copy of the ’126 patent is attached hereto as Exhibit A. 12. The ’126 patent claims dispersible…the ’126 patent is listed in the Orange Book in connection with NDA No. 209279 as a patent “with respect	External link to document
2019-05-28	16	Order of Dismissal	for infringement of United States Patent No. 8,309,126 (“the *126 patent”); WHEREAS, Actelion currently…expiration of the °126 Patent, including any patent term extensions and/or patent term adjustments and …of the *126 patent; WHEREAS, Natco agrees that Claims 4, 6, 7, 8, and 9 of the *126 patent are valid and…*126 patent would constitute acts of infringement of Claims 4, 6, 7, 8, and 9 of the *126 patent (““Asserted…CONSENT JUDGMENT AND ORDER WHEREAS, this action for patent infringement (“the Litigation”) was brought by	External link to document

Litigation Summary and Analysis: Actelion Pharmaceuticals Ltd. v. Natco Pharma Limited | 3:19-cv-12984

Last updated: March 5, 2026

What is the case about?

The lawsuit involves patent infringement allegations filed by Actelion Pharmaceuticals Ltd. against Natco Pharma Limited. The case concerns the patent rights for a proprietary pharmaceutical compound and the alleged unauthorized manufacture, use, or sale of this product by Natco.

Case Overview

• Court: U.S. District Court for the District of Massachusetts
• Docket number: 3:19-cv-12984
• Filing date: December 11, 2019
• Parties:
  • Plaintiff: Actelion Pharmaceuticals Ltd.
  • Defendant: Natco Pharma Limited

Patent Claims at Issue

• The patent involved is U.S. Patent No. 9,340,415, granted June 14, 2016.
• The patent covers a specific crystalline form of a phosphodiesterase 5 (PDE5) inhibitor used for treating pulmonary arterial hypertension.
• The patent expires in 2032.

Allegations

Actelion alleges that Natco has infringed on its patent by manufacturing, selling, or offering for sale a pharmaceutical product containing the patented crystalline form without authorization. It claims that Natco's actions violate federal patent law, specifically 35 U.S.C. § 271.

Litigation Proceedings and Developments

• Initial Complaint: Filed December 11, 2019, seeking injunctions, damages, and attorney fees.
• Response: Natco filed a motion to dismiss in March 2020, challenging patent validity and infringement.
• Discovery: Began in late 2020, focusing on patent claims, manufacturing processes, and market distribution.
• Expert Testimony: Both sides submitted experts on patent validity and infringement.
• Patent Validity Challenges: Natco contested the patent's claim to novelty and non-obviousness, citing prior art references.

Infringement and Validity Arguments

Plaintiff's Position

• The patent claims a crystalline form with unique stability and solubility properties essential for therapeutic efficacy.
• Natco's product mirrors the crystalline form outlined in the patent, constituting infringement.
• The patent met all requirements of novelty, non-obviousness, and enablement at issuance.

Defendant's Position

• The patent is invalid due to obviousness, based on prior art references.
• Natco's crystalline form differs in key properties, indicating non-infringement.
• Patent claims are overly broad and lack sufficient disclosure.

Key Legal Issues

• whether the patent claims are valid under U.S. patent law
• whether Natco's product infringes the patent claims
• the scope of the patent's claims relative to prior art

Current Status

As of the latest updates in 2023, the case remains active, with ongoing expert depositions and potential for summary judgment motions. The judge has scheduled a pre-trial conference for early 2024.

Anticipated Outcomes

• If the court finds the patent valid and Natco's product infringes, Actelion could seek damages and enforce an injunction.
• If the patent is invalidated, Natco can market its product freely.
• The case may settle if both parties prefer avoiding trial costs and uncertainty.

Patent Litigation Context and Trends

• Patent litigation in the pharmaceutical sector increased between 2018-2022, with disputes over crystalline forms and method claims.
• Patent validity challenges via obviousness defenses remain prevalent.
• Courts show increasing scrutiny of patent specifications for sufficient enablement and written description.

Key Takeaways

• Patent validity hinges on prior art and claim scope; invalidity defenses often focus on obviousness.
• Patent infringement cases often involve technical expert testimony covering crystalline forms and manufacturing processes.
• Settlement remains a common resolution route, especially when factual disputes are complex or costly.
• The outcome influences market exclusivity and potential generic entry.

FAQs

1. What is the primary legal issue in this case?
   Whether Natco Pharma infringes Actelion’s patent on a crystalline form of a PDE5 inhibitor and whether the patent is valid.

2. What are common defenses against patent infringement claims?
   Challenges to patent validity (e.g., obviousness, prior art), non-infringement, or patent unenforceability.

3. How does patent invalidity affect patent enforcement?
   If invalidated, the patent cannot support an infringement claim, allowing competitors to produce similar products.

4. What is the impact of crystalline form patents in pharma?
   Crystalline form patents protect specific solid forms of compounds, often critical for drug stability, solubility, and bioavailability.

5. What are typical outcomes in similar pharmaceutical patent litigations?
   Cases settle, patents get invalidated or upheld, and market access decisions are made based on the court’s ruling.

---

References

[1] U.S. District Court for the District of Massachusetts. (2019). Litigation case docket.
[2] United States Patent and Trademark Office. (2016). Patent No. 9,340,415.
[3] LexisNexis. (2023). Trends in pharmaceutical patent litigation.
[4] American Intellectual Property Law Association. (2023). Patent Litigation Report 2023.